IL-1β breaks tolerance through expansion of CD25+ effector T cells

Journal of Immunology

Volumn 176, Issue 12, 2006, Pages 7278-7287

  O'Sullivan, Brendan J ^a   Thomas, Helen E ^b   Pai, Saparna ^a   Santamaria, Pere ^c   Iwakura, Yoichiro ^d   Steptoe, Raymond J ^a   Kay, Thomas W H ^b   Thomas, Ranjeny ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Julia McFarlane Diabetes Research Centre   (Australia)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 33744921639     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.12.7278     Document Type: Article

References (53)

1. Timms, A. E., A. M. Crane, A. M. Sims, H. J. Cordell, L. A. Bradbury, A. Abbott, M. R. Coyne, O. Beynon, I. Herzberg, G. W. Duff, A. Calin, et al. 2004. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am. J. Hum. Genet. 75: 587-595.
2. Pascual, V., F. Allantaz, E. Arce, M. Punaro, and J. Banchereau. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201: 1479-1486.
3. Maeda, S., L. C. Hsu, H. Liu, L. A. Bankston, M. Iimura, M. F. Kagnoff, L. Eckmann, and M. Karin. 2005. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 307: 734-738.
4. Agostini, L., F. Martinon, K. Bums, M. F. McDermott, P. N. Hawkins, and J. Tschopp. 2004. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20: 319-325.
5. Firestein, G. S. 2004. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J. Clin. Invest. 114: 471-474.
6. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313-320.
7. Ohmura, K., A. Johnsen, A. Ortiz-Lopez, P. Desany, M. Roy, W. Besse, J. Rogus, M. Bogue, A. Puech, M. Lathrop, et al. 2005. Variation in IL-1β gene expression is a major determinant of genetic differences in arthritis aggressivity in mice. Proc. Natl. Acad. Sci. USA 102: 12489-12494.
8. Ji, H., A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, and C. Benoist. 2002. Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis. J. Exp. Med. 196: 77-85.
9. Heraud, F., A. Heraud, and M. F. Harmand. 2000. Apoptosis in normal and osteoarthritic human articular cartilage. Ann. Rheum. Dis. 59: 959-965.
10. Mandrup-Poulsen, T., G. A. Spinas, S. J. Prowse, B. S. Hansen, D. W. Jorgensen, K. Bendtzen, J. H. Nielsen, and J. Nerup. 1987. Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes 36: 641-647.
11. Eriksson, U., M. O. Kurrer, I. Sonderegger, G. Iezzi, A. Tafuri, L. Hunziker, S. Suzuki, K. Bachmaier, R. M. Bingisser, J. M. Penninger, and M. Kopf. 2003. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J. Exp. Med. 197: 323-331.
12. Ruprecht, C. R., M. Gattorno, F. Ferlito, A. Gregorio, A. Martini, A. Lanzavecchia, and F. Sallusto. 2005. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. 201: 1793-1803.
13. Kubo, T., R. D. Hatton, J. Oliver, X. Liu, C. O. Elson, and C. T. Weaver. 2004. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J. Immunol. 173: 7249-7258.
14. Belghith, M., J. A. Bluestone, S. Barriot, J. Megret, J. F. Bach, and L. Chatenoud. 2003. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9: 1202-1208.
15. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, and J. A. Bluestone. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455-1465:
16. Katz, J. D., B. Wang, K. Haskins, C. Benoist, and D. Mathis. 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74: 1089-1100.
17. Schmidt, D., J. Verdaguer, N. Averill, and P. Santamaria. 1997. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. J. Exp. Med. 186: 1059-1075.
18. Steptoe, R. J., S. Stankovic, S. Lopaticki, L. K. Jones, L. C. Harrison, and G. Morahan. 2004. Persistence of recipient lymphocytes in NOD mice after irradiation and bone marrow transplantation. J. Autoimmun. 22: 131-138.
19. Thomas, H. E., W. Irawaty, R. Darwiche, T. C. Brodnicki, P. Santamaria, J. Allison, and T. W. Kay. 2004. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 53: 113-121.
20. O'Sullivan, B. J., and R. Thomas. 2002. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-κB. J. Immunol. 168: 5491-5498.
21. Pasare, C, and R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25 + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
22. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200: 277-285.
23. Shevach, E. M. 2000. Regulatory T cells in autoimmunity. Annu Rev Immunol. 18: 423-449.
24. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25 + regulatory T cells. Nat. Immunol. 4: 330-336.
25. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
26. Fontenot, J. D., J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, and A. Y. Rudensky. 2005. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329-341.
27. Bettelli, E., M. Dastrange, and M. Oukka. 2005. Foxp3 interacts with nuclear factor of activated T cells and NF-κB to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl. Acad. Sci. USA 102: 5138-5143.
28. Heufler, C., F. Koch, and G. Schuler. 1988. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167: 700-705.
29. Luft, T., M. Jefford, P. Luetjens, H. Hochrein, K. A. Masterman, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky. 2002. IL-1β enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J. Immunol. 168: 713-722.
30. Yamazaki, S., T. Iyoda, K. Tarbell, K. Olson, K. Velinzon, K. Inaba, and R. M. Steinman. 2003. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198: 235-247.
31. Pop, S. M., C. P. Wong, D. A. Culton, S. H. Clarke, and R. Tisch. 2005. Single cell analysis shows decreasing FoxP3 and TGFβ1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J. Exp. Med. 201: 1333-1346.
32. Yaacob, N. S., M. A. Kaderi, and M. N. Norazmi. 2004. The expression of cytokine genes in the peritoneal macrophages and splenic CD4- and CD8-positive lymphocytes of the nonobese diabetic mice. J. Clin. Immunol. 24: 177-184.
33. Dinarello, C. A. 2004. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. 4: 378-385.
34. Alyanakian, M. A., S. You, D. Damotte, C. Gouarin, A. Esling, C. Garcia, S. Havouis, L. Chatenoud, and J. F. Bach. 2003. Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases. Proc. Natl. Acad. Sci. USA 100: 15806-15811.
35. Andre, I., A. Gonzalez, B. Wang, J. Katz, C. Benoist, and D. Mathis. 1996. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl. Acad. Sci. USA 93: 2260-2263.
36. Arif, S., T. I. Tree, T. P. Astill, J. M. Tremble, A. J. Bishop, C. M. Dayan, B. O. Roep, and M. Peakman. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113: 451-463.
37. Hill, N. J., K. Van Gunst, and N. Sarvetnick. 2003. Th1 and Th2 pancreatic inflammation differentially affects homing of islet-reactive CD4 cells in nonobese diabetic mice. J. Immunol. 170: 1649-1658.
38. Walker, M. R., D. J. Kasprowicz, V. H. Gersuk, A. Benard, M. Van Landeghen, J. H. Buckner, and S. F. Ziegler. 2003. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 112: 1437-1443.
39. + regulatory T cells in antitumor immune response. J. Immunol. 175: 4433-4440.
40. Liston, A., S. Lesage, D. H. Gray, L. A. O'Reilly, A. Strasser, A. M. Fahrer, R. L. Boyd, J. Wilson, A. G. Baxter, E. M. Gallo, et al. 2004. Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity 21: 817-830.
41. + T cells. J. Immunol. 173: 5008-5020.
42. Jaeckel, E., H. von Boehmer, and M. P. Manns. 2005. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 54:306-310.
43. Brennan, F. M., D. Chantry, A. Jackson, R. Maini, and M. Feldmann. 1989. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244-247.
44. Feldmann, M., and R. N. Maini. 2001. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196.
45. Martinon, F., and J. Tschopp. 2004. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561-574.
46. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
47. He, X., E. F. Rosloniec, L. K. Myers, W. L. McColgan 3rd, M. Gumanovskaya, A. H. Kang, and J. M. Stuart. 2004. T cell receptors recognizing type II collagen in HLA-DR-transgenic mice characterized by highly restricted V β usage. Arthritis Rheum. 50: 1996-2004.
48. Dessen, A., C. M. Lawrence, S. Cupo, D. M. Zaller, and D. C. Wiley. 1997. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7: 473-481.
49. Nakae, S., M. Asano, R. Horai, N. Sakaguchi, and Y. Iwakura. 2001. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J. Immunol. 167: 90-97.
50. Hiltunen, M., H. Hyoty, M. Knip, J. Ilonen, H. Reijonen, P. Vahasalo, M. Roivainen, M. Lonnrot, P. Leinikki, T. Hovi, and H. K. Akerblom. 1997. Islet cell antibody seroconversion in children is temporally associated with enterovirus infections. Childhood Diabetes in Finland (DiMe) Study Group. J. Infect. Dis. 175: 554-560.
51. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191: 1649-1660.
52. Scofield, R. H. 2004. Autoantibodies as predictors of disease. Lancet 363: 1544-1546.
53. Achenbach, P., K. Koczwara, A. Knopff, H. Naserke, A. G. Ziegler, and E. Bonifacio. 2004. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J. Clin. Invest. 114: 589-597.